Navigation Links
FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications
Date:3/16/2011

SILVER SPRING, Md., March 16, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration and the European Medicines Agency (EMA) have launched a new pilot program that will allow parallel evaluation of relevant development and manufacturing data components, known as Quality by Design (QbD), of new drug marketing applications that are submitted to both agencies.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The parallel evaluation within this voluntary pilot program means that reviewers from both agencies will separately assess the quality/chemistry, manufacturing and control (CMC) section of the new drug applications (NDAs) submitted to the FDA and marketing authorization applications (MAAs) submitted to the EMA.  However, there will be regular communication and consultation between European regulators and their U.S. colleagues throughout the review process relevant to QbD aspects of the applications.  

QbD in pharmaceuticals involves designing and developing pharmaceutical formulations and manufacturing processes to help ensure product manufacturing quality. Several guidelines have been developed by the International Conference on Harmonisation (ICH) to harmonize and facilitate the implementation of QbD. This pilot program began out of concern that certain ICH guidelines were being interpreted differently in Europe and the United States. Goals of the pilot program include:  

  • Helping to ensuring consistent implementation of ICH guidelines for manufacturing quality in the application evaluation process
  • Increasing awareness of these regulatory concepts by staff that review marketing applications and inspect manufacturing facilities as part of the approval process
  • Defining the reviewer and inspector interaction for QbD applications
  • Creating a further way for EMA and FDA assessors/reviewers to share full knowledge about these applications
  • Developing and harmonizing regulatory decisions to the greatest extent possible.

"As the number of applications that follow the QbD approach steadily increases, collaborative assessments will enhance understanding of QbD concepts. The tools used by FDA and EU reviewers will increase information sharing and reduce redundancy," said Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research. "To fully implement QbD, we need to further harmonize the implementation of the guidelines, work collaboratively, and provide scientific, risk-based regulatory decisions in a timely manner."

"This is another concrete example of the very collaborative working relationship we have with our European regulatory colleagues and how we can leverage the scientific resources we both have for the benefit of our agencies and our citizens," said Murray M. Lumpkin, M.D., Deputy Commissioner of FDA's Office of International Programs.  

This pilot program applies to NDAs and MAAs, some supplements, and CMC meeting requests that include QbD elements submitted to both agencies at about the same time. The pilot will only include chemical entities and not biologically-derived products. Review of QbD applications does not change statutory deadlines. The pilot will end on March 31, 2014.

For more information:

International Conference on Harmonization - Quality Guidance

European Medicines Agency

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
2. Shanghai ChemPartner Announces Being Selected as Antibody Service Partner by Shenogen Pharma Group
3. China Nepstar Chain Drugstore Announces Management Appointments
4. Nephros Announces Split Adjusted Trade Date
5. Harris Corporation and Johns Hopkins Medicine Announce Joint Venture to Develop Innovative Medical Image Management Solutions
6. Bionovo Announces 2010 Highlights and Year-End Financial Results
7. Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
8. The Electro-Nail - Better Design for Faster Healing. ICAP Ocean Tomo Announces Auction of an Advanced Electro-Nail Implant System for Electro-Magnetic Bone Stimulation in Orthopedics
9. Healthier Healing for Hip Resurfacing - ICAP Ocean Tomo Announces Auction of an Advanced Hip Cap for Electromagnetic Tissue Stimulation by Neue Magnetodyn.
10. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
11. China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior ... executive officer, today. In his new role, Marziani will lead the company,s business development ... professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... -- Open Access Journal Focusing on ... Elsevier , a world-leading provider of scientific, technical ... launch of Clinical Neurophysiology Practice ... clinical practice issues in clinical neurophysiology. The journal will ... and didactic reviews. It is an official journal of ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human interest stories, courtesy of leaders in ... trends and tech within the industry, from leading advocates and associations—namely Jones & ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
Breaking Medicine News(10 mins):